Chris Raymond
Stock Analyst at Raymond James
(2.96)
# 1,523
Out of 5,050 analysts
8
Total ratings
75%
Success rate
25.23%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Chris Raymond
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MNPR Monopar Therapeutics | Maintains: Strong Buy | $80 → $142 | $80.95 | +75.42% | 2 | Oct 6, 2025 | |
| SION Sionna Therapeutics | Initiates: Strong Buy | $45 | $34.71 | +29.65% | 1 | Sep 3, 2025 | |
| TYRA Tyra Biosciences | Initiates: Strong Buy | $35 | $14.32 | +144.41% | 1 | Sep 3, 2025 | |
| NUVL Nuvalent | Initiates: Outperform | $105 | $93.35 | +12.48% | 1 | Sep 3, 2025 | |
| KLRS Kalaris Therapeutics | Initiates: Strong Buy | $23 | $4.75 | +384.21% | 1 | Sep 3, 2025 | |
| COGT Cogent Biosciences | Initiates: Strong Buy | $30 | $14.82 | +102.43% | 1 | Sep 3, 2025 | |
| BHVN Biohaven | Initiates: Strong Buy | $75 | $8.26 | +807.99% | 1 | Sep 3, 2025 |
Monopar Therapeutics
Oct 6, 2025
Maintains: Strong Buy
Price Target: $80 → $142
Current: $80.95
Upside: +75.42%
Sionna Therapeutics
Sep 3, 2025
Initiates: Strong Buy
Price Target: $45
Current: $34.71
Upside: +29.65%
Tyra Biosciences
Sep 3, 2025
Initiates: Strong Buy
Price Target: $35
Current: $14.32
Upside: +144.41%
Nuvalent
Sep 3, 2025
Initiates: Outperform
Price Target: $105
Current: $93.35
Upside: +12.48%
Kalaris Therapeutics
Sep 3, 2025
Initiates: Strong Buy
Price Target: $23
Current: $4.75
Upside: +384.21%
Cogent Biosciences
Sep 3, 2025
Initiates: Strong Buy
Price Target: $30
Current: $14.82
Upside: +102.43%
Biohaven
Sep 3, 2025
Initiates: Strong Buy
Price Target: $75
Current: $8.26
Upside: +807.99%